Molnlycke

Mölnlycke, a Swedish pharmaceutical preparation manufacturer, reported total global greenhouse gas emissions of approximately 533.1 million kg CO2e in 2025. This includes Scope 1 emissions of about 47.9 million kg CO2e, market-based Scope 2 emissions of approximately 1.9 million kg CO2e, and Scope 3 emissions totalling around 483.3 million kg CO2e. Key contributors to Scope 3 emissions in 2025 were purchased goods and services (approximately 295.1 million kg CO2e) and capital goods (around 78.1 million kg CO2e).

Looking back, Mölnlycke's total emissions were approximately 548.8 million kg CO2e in 2024, and 518.0 million kg CO2e in 2023. In 2022, total emissions stood at about 581.5 million kg CO2e, and in 2021, they were around 648.9 million kg CO2e.

Mölnlycke has made significant climate commitments. The company aims to achieve net-zero greenhouse gas emissions across its value chain by 2050. Specifically, Mölnlycke Health Care AB has committed to Science Based Targets initiative (SBTi) approved targets:

• To reduce absolute Scope 1 and 2 greenhouse gas emissions by 50% by 2030, from a 2021 base year.
• To increase active annual sourcing of renewable electricity from 23% in 2021 to 100% by the end of 2024, and maintain 100% renewable electricity sourcing through 2030.
• To reduce absolute Scope 3 greenhouse gas emissions from purchased goods and services, fuel and energy related activities, upstream transportation and distribution, and waste generated in operations by 20% by 2028, from a 2021 base year.
• Furthermore, 63% of its suppliers (by emissions covering purchased goods and services, capital goods, and upstream transportation and distribution) are committed to having science-based targets by 2028.
• For its long-term targets, Mölnlycke Health Care commits to reducing absolute Scope 1 and 2 greenhouse gas emissions by 90% by 2050 from a 2021 base year, and to reducing Scope 3 greenhouse gas emissions by 97% per tonne of sold product within the same timeframe.